加载中
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
前收盘价
US$2.51
+US$0.14 · +5.91%
盘前
US$2.52
+US$0.01 · +0.40%
10月12日 5:40 ET
盘中时间采用ET。市场数据可能有所延迟。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日内区间
当前US$2.51
52周区间
当前US$2.51
盘中时间采用ET。市场数据可能有所延迟。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日内区间
当前US$2.51
52周区间
当前US$2.51
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 934.1万 USD | 725.11万 USD | 762.17万 USD | 632.47万 USD | 252.32万 USD |
| 销售、一般及管理费用 | 1049.26万 USD | 811.47万 USD | 875.68万 USD | 858.62万 USD | 520.6万 USD |
| 营业费用 | 1983.35万 USD | 1536.58万 USD | 1637.85万 USD | 1491.09万 USD | 772.91万 USD |
| 利息收入 | — | — | — | 58.81万 USD | 1.77万 USD |
| 折旧和摊销 | — | 735 USD | 1284 USD | 1781 USD | 1403 USD |
| 营业利润 | −1983.35万 USD | −1536.58万 USD | −1637.85万 USD | −1491.09万 USD | −772.91万 USD |
| 净利润 | −2084.89万 USD | −1502.2万 USD | −1542.35万 USD | −1432.28万 USD | −771.14万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年6月27日 | 1:28 | — | — |
股票拆分 | 2021年7月27日 | 1:4 | — | — |
股票拆分 | 2020年10月30日 | 1:20 | — | — |
已生效 2025年6月27日
1:28
已生效 2021年7月27日
1:4
已生效 2020年10月30日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
